---
$id: https://graph.org.ai/products/commodity/51142521
$type: Product
source: UNSPSC
code: "51142521"
title: "Ciladopa"
class: "51142500"
classTitle: "Antiparkinson drugs"
family: "51140000"
familyTitle: "Central nervous system drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Ciladopa

**UNSPSC Code**: 51142521
**Class**: [Antiparkinson drugs](Antiparkinson drugs.mdx)
**Family**: [Central nervous system drugs](../Central nervous system drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a dopamine agonist with the molecular formula C21H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D09L486R3J, chemically known as 2,4,6-cycloheptatrien-1-one, 2-(4-(2-(3,4-dimethoxyphenyl)-2-hydroxyethyl)-1-piperazinyl)-, (s)- but generally known as ciladopa, which bears US NIH Compound Identifier 133371. European Medicines Agency schedules Ciladopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06262MIG. The term CILADOPA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). CILADOPA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ciladopa under HS 29335995 and SITC 51576. As of Q4 2014, CILADOPA remains the US FDA Preferred Term for this commodity. Ciladopa bears US NLM identifiers UMLS ID C0055722 and NCI Concept Code C79568. SMILES: OC(CN1CCN(CC1)C1C(=O)CCCCC1)C1CC(OC)C(OC)CC1.

